PDCD1 and hepatocellular carcinoma: The incidence of drug-induced liver injury varies depending on agent type and dosage in HCC patients receiving PD-1 inhibitors, often manifesting as dose-dependent elevations in alanine aminotransferase (ALT) levels (9).